

Ask Pfizer to help adrenal insufficient patients to obtain Solu-Cortef during the shortage
The Issue
Adrenal insufficiency is a rare disease in which a patient's body fails to produce sufficient amounts of the hormone cortisol, one of the few life-sustaining hormones in the human body. Cortisol is an essential hormone that affects almost every organ and tissue in the body. It plays many important roles, including regulating blood pressure and blood sugar, helping to control sleep-wake cycles, reducing inflammation and regulating the body's stress-response. (Footnote 1) Patients suffering from adrenal insufficiency require a daily replacement medication, typically in the form of a glucocorticoid. In addition, some patients require treatment with a mineralocorticoid. All adrenal insufficient patients are at risk for a potentially life-threatening adrenal crisis. "Adrenal crisis is a life-threatening medical emergency, associated with a high mortality unless it is appropriately recognized and early treatment is rendered. Despite it being a treatable condition for almost 70 years, failure of adequate preventive measures or delayed treatment has often led to unnecessary deaths." (Footnote 2) That is why all major organizations including the National Institutes of Health, Mayo Clinic, Adrenal Insufficiency United and the National Adrenal Diseases Foundation (to name just a few) recommend that every adrenal insufficient patient be equipped with an emergency injection kit, with injectable hydrocortisone (Solu-Cortef) being the "preferred emergency glucocorticoid." (Footnote 3)
In addition, some patients that have failed to stabilize on conventional treatment with oral glucocorticoids utilize daily injectable glucocorticoids, most commonly Solu-Cortef. There currently is no generic injectable hydrocortisone available on the US market, meaning these patients are left with few alternatives. Namely injectable Solu-Medrol (methylprednisolone) or Dexamethasone. Both of these alternatives have a different duration of action and are supplied in different ratios, meaning they would require a patient to relearn an entirely new dosing plan that requires different timing of doses and different amounts of medication to be injected. This leaves patients incredibly vulnerable to potential mistakes and resulting over- or under-replacement. Therefore, this should only be considered as an absolute last resort.
Given the crucial role of Solu-Cortef as both an emergency injection and daily replacement medication, it is incredibly concerning to the adrenal insufficient patient population that an ever increasing amount of pharmacies is unable to supply patients with this essential medication. IV hydrocortisone is further identified under Executive Order 13944 as an essential medication, an order aimed at having the FDA identify medicines that are "medically necessary to have available at all times in an amount adequate to serve patient needs." (Footnote 4) Pfizer has confirmed on the phone as of 3/13/23 that Solu-Cortef is only available in "incredibly limited amount." They have restricted any orders from wholesalers or distributors and are currently drop-shipping it to hospitals or pharmacies only. Their estimated next shipment is June of 2023, which Pfizer expressly stated was not a guaranteed re-supply date and "subject to change." This causes significant issues for many patients whose pharmacies and doctors are struggling to obtain accurate information on the shortage and potential options. Many pharmacies are claiming they are not set up to receive direct shipments, have contracts with distributors that prevent them from accepting direct shipments from pharmaceutical companies or merely do not have the staffing to navigate lengthy phone calls and the paperwork associated with the process. Therefore, we are very kindly asking Pfizer to provide the adrenal insufficient community with some crucial information regarding the shortage. We'd love to have a direct contact with Pfizer that can provide affected patients with accurate information and timely assistance in navigating the drop ship process. Pfizer's online email form is limited to 500 characters and seems unfortunately overwhelmed with responding in a timely manner. The phone system for the drop ship process is a line exclusively for medical professionals, leaving patients without a means to assist their care team in navigating this process. Alternatively, we ask that Pfizer considers setting up a website to inform patients and medical professionals with accurate information and timely updates on the Solu-Cortef shortage and the exact requirements for a pharmacy to request a drop shipment of Solu-Cortef for affected patients. Thank you!
Footnote 1: https://my.clevelandclinic.org/health/articles/22187-cortisol
Footnote 2: Puar, T., et al. “Adrenal Crisis: Still a Deadly Event in the 21st Century," 2015, DOI: https://doi.org/10.1016/j.amjmed.2015.08.021
Footnote 3: Adrenal Insufficieny United, Emergency Info, 2023, https://united4rare.org/emergency-info/; https://www.nadf.us/uploads/1/3/0/1/130191972/emergency_injection_kit_instructions.pdf; https://www.niddk.nih.gov/health-information/endocrine-diseases/adrenal-insufficiency-addisons-disease/all-content; https://www.mayoclinic.org/diseases-conditions/addisons-disease/diagnosis-treatment/drc-20350296
911
The Issue
Adrenal insufficiency is a rare disease in which a patient's body fails to produce sufficient amounts of the hormone cortisol, one of the few life-sustaining hormones in the human body. Cortisol is an essential hormone that affects almost every organ and tissue in the body. It plays many important roles, including regulating blood pressure and blood sugar, helping to control sleep-wake cycles, reducing inflammation and regulating the body's stress-response. (Footnote 1) Patients suffering from adrenal insufficiency require a daily replacement medication, typically in the form of a glucocorticoid. In addition, some patients require treatment with a mineralocorticoid. All adrenal insufficient patients are at risk for a potentially life-threatening adrenal crisis. "Adrenal crisis is a life-threatening medical emergency, associated with a high mortality unless it is appropriately recognized and early treatment is rendered. Despite it being a treatable condition for almost 70 years, failure of adequate preventive measures or delayed treatment has often led to unnecessary deaths." (Footnote 2) That is why all major organizations including the National Institutes of Health, Mayo Clinic, Adrenal Insufficiency United and the National Adrenal Diseases Foundation (to name just a few) recommend that every adrenal insufficient patient be equipped with an emergency injection kit, with injectable hydrocortisone (Solu-Cortef) being the "preferred emergency glucocorticoid." (Footnote 3)
In addition, some patients that have failed to stabilize on conventional treatment with oral glucocorticoids utilize daily injectable glucocorticoids, most commonly Solu-Cortef. There currently is no generic injectable hydrocortisone available on the US market, meaning these patients are left with few alternatives. Namely injectable Solu-Medrol (methylprednisolone) or Dexamethasone. Both of these alternatives have a different duration of action and are supplied in different ratios, meaning they would require a patient to relearn an entirely new dosing plan that requires different timing of doses and different amounts of medication to be injected. This leaves patients incredibly vulnerable to potential mistakes and resulting over- or under-replacement. Therefore, this should only be considered as an absolute last resort.
Given the crucial role of Solu-Cortef as both an emergency injection and daily replacement medication, it is incredibly concerning to the adrenal insufficient patient population that an ever increasing amount of pharmacies is unable to supply patients with this essential medication. IV hydrocortisone is further identified under Executive Order 13944 as an essential medication, an order aimed at having the FDA identify medicines that are "medically necessary to have available at all times in an amount adequate to serve patient needs." (Footnote 4) Pfizer has confirmed on the phone as of 3/13/23 that Solu-Cortef is only available in "incredibly limited amount." They have restricted any orders from wholesalers or distributors and are currently drop-shipping it to hospitals or pharmacies only. Their estimated next shipment is June of 2023, which Pfizer expressly stated was not a guaranteed re-supply date and "subject to change." This causes significant issues for many patients whose pharmacies and doctors are struggling to obtain accurate information on the shortage and potential options. Many pharmacies are claiming they are not set up to receive direct shipments, have contracts with distributors that prevent them from accepting direct shipments from pharmaceutical companies or merely do not have the staffing to navigate lengthy phone calls and the paperwork associated with the process. Therefore, we are very kindly asking Pfizer to provide the adrenal insufficient community with some crucial information regarding the shortage. We'd love to have a direct contact with Pfizer that can provide affected patients with accurate information and timely assistance in navigating the drop ship process. Pfizer's online email form is limited to 500 characters and seems unfortunately overwhelmed with responding in a timely manner. The phone system for the drop ship process is a line exclusively for medical professionals, leaving patients without a means to assist their care team in navigating this process. Alternatively, we ask that Pfizer considers setting up a website to inform patients and medical professionals with accurate information and timely updates on the Solu-Cortef shortage and the exact requirements for a pharmacy to request a drop shipment of Solu-Cortef for affected patients. Thank you!
Footnote 1: https://my.clevelandclinic.org/health/articles/22187-cortisol
Footnote 2: Puar, T., et al. “Adrenal Crisis: Still a Deadly Event in the 21st Century," 2015, DOI: https://doi.org/10.1016/j.amjmed.2015.08.021
Footnote 3: Adrenal Insufficieny United, Emergency Info, 2023, https://united4rare.org/emergency-info/; https://www.nadf.us/uploads/1/3/0/1/130191972/emergency_injection_kit_instructions.pdf; https://www.niddk.nih.gov/health-information/endocrine-diseases/adrenal-insufficiency-addisons-disease/all-content; https://www.mayoclinic.org/diseases-conditions/addisons-disease/diagnosis-treatment/drc-20350296
Supporter Voices
Petition Updates
Share this petition
Petition created on March 22, 2023